tbuckley/cabot-search huggingface dataset:
Temsirolimus in second or subsequent line in patients with metastatic renal cell carcinoma (mRCC): Better activity in good-intermediate prognosis patients.
Authors: G. Vitali, M. Duca, C. Fugazza, S. Longoni, S. Trinca, D. Ceraulo, E. Villa, M. Bregni
Journal: Journal of Clinical Oncology (2010)

e15081 Background: To evaluate the activity and safety of the inhibitor of mammalian target of rapamycin (mTOR) temsirolimus in unselected, pre-treated patients with mRCC. Methods: Eligible cases had mRCC of clear or non-clear renal cell histology and accessibility for treatment. Any previous treatment was allowed. Patients received 25 mg of intravenous temsirolimus on a weekly basis in the context of a IRB-approved compassionate-use protocol, and were evaluated every 8 weeks for toxicity and tumor response. Results: From March 2007 to date 34 patients have been evaluated and 28 treated (median age 54, range 24-76; male/female ratio: 22/6; clear vs non-clear histology: 23/4, one case not evaluable for histology; 18 cases were treated with sorafenib, 23 with sunitinib and 13 with both drugs). Median number of previous treatments was 2 (range 0-5). According to the Motzer prognostic criteria, 17 were classified as poor-risk, 9 as good-intermediate risk, and 2 had an unknown status. Most common treatment-related adverse events, mainly of grade 1-2, were: hypercholesterolemia, hypertriglyceridemia, anemia, hyperglycemia, neutropenia, lymphocytopenia, stomatitis, skin rash. Dose reduction has been provided in 25% of the cases. Of 28 patients with an available actual tumour re-evaluation none qualified for objective response, 16 achieved a stable disease (57%) and 12 progressed (43%). Considering the prognostic criteria, 9/17 (35%) poor-risk and 8/9 (89%) good-intermediate risk patients achieved a stable disease. All the 4 patients with non-clear-cell histology reported a progressive disease within the first 8 weeks. With a median follow-up of 9 months (range 1-26+) the mean (median) PFS was 5.9 (3.6) months. The median overall survival from the onset of metastatic disease is 28 months (mean OS 42.4 months, range 4-161+ months). The median number of cycles administered was 13. Conclusions: temsirolimus confirms its activity and good safety profile also in a heavily pre-treated population of refractory/relapsed mRCC patients. Further investigations of this drug are warranted. No significant financial relationships to disclose.
The Policy Dystopia Model: An Interpretive Analysis of Tobacco Industry Political Activity
Authors: Selda Ulucanlar, Gary J. Fooks, Anna B. Gilmore
Journal: PLoS Medicine (2016)

Tobacco industry interference has been identified as the greatest obstacle to the implementation of evidence-based measures to reduce tobacco use. Understanding and addressing industry interference in public health policy-making is therefore crucial. Existing conceptualisations of corporate political activity (CPA) are embedded in a business perspective and do not attend to CPA's social and public health costs; most have not drawn on the unique resource represented by internal tobacco industry documents. Building on this literature, including systematic reviews, we develop a critically informed conceptual model of tobacco industry political activity.We thematically analysed published papers included in two systematic reviews examining tobacco industry influence on taxation and marketing of tobacco; we included 45 of 46 papers in the former category and 20 of 48 papers in the latter (n = 65). We used a grounded theory approach to build taxonomies of "discursive" (argument-based) and "instrumental" (action-based) industry strategies and from these devised the Policy Dystopia Model, which shows that the industry, working through different constituencies, constructs a metanarrative to argue that proposed policies will lead to a dysfunctional future of policy failure and widely dispersed adverse social and economic consequences. Simultaneously, it uses diverse, interlocking insider and outsider instrumental strategies to disseminate this narrative and enhance its persuasiveness in order to secure its preferred policy outcomes. Limitations are that many papers were historical (some dating back to the 1970s) and focused on high-income regions.The model provides an evidence-based, accessible way of understanding diverse corporate political strategies. It should enable public health actors and officials to preempt these strategies and develop realistic assessments of the industry's claims.
Hepatocyte-Specific SMAD7 Deletion Accelerates Den Induced Mouse Hepatocellular Carcinoma via Activation of STAT3 Signaling
Authors: T. Feng, J. Dzieran, T. Maass, A. Teufel, S. Marhenke, A. Vogel, S. Dooley, N. Meindl-Beinker
Journal: Journal of Hepatology (2016)
HMGB1 in Steatotic and Non-Steatotic Liver Transplantation from brain- Dead Donors with Previous Ischemic Preconditioning
Authors: M.B. Jimenez-Castro, E. Negrete-Sanchez, C.A. de León, A. Casillas-Ramírez, M.E. Cornide-Petronio, E. Bujaldon, M. Mendes-Braz, J. Gulfo, J. Gracia-Sancho, J. Rodés, C. Peralta
Journal: Journal of Hepatology (2016)
Risk Assessment of Hepatocellular Carcinoma using Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Chronic Hepatitis B Patients
Authors: J.Y. Heo, S.S. Ahn, S.U. Kim, B.K. Kim, J.Y. Park, D.Y. Kim, S.H. Ahn, H.-S. Kim, Y.N. Park, K.-H. Han
Journal: Journal of Hepatology (2016)
Easl-Aleh Guidelines for the Non-Invasive Evaluation of Liver Disease Severity in Chronic Hepatitis B: An Independent Validation
Authors: J.K. Nana, K. Skaare, T. Asselah, M. Adler, M.N. Hilleret, J.P. Zarski, A. Marlu, J.L. Bosson, V. Leroy
Journal: Journal of Hepatology (2016)
One Year Mortality in STEMI Patients Randomized to Primary PCI or a Pharmaco-invasive Strategy. The Stream 1 Year Follow-up
Authors: Peter Sinnaeve, Paul Armstrong, Anthony Gershlick, Patrick Goldstein, Robert Wilcox, Thierry Danays, Louis Soulat, Katleen Vandenberghe, Anne Regelin, Kris Bogaerts, Frans Van de Werf
Journal: Circulation (2013)
Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy
Authors: Gregory S. Alexander, Joshua D. Palmer, Madalina Tuluc, Jianqing Lin, Adam P. Dicker, Voichita Bar-Ad, Larry A Harshyne, Jennifer Louie, Colette M. Shaw, D. Craig Hooper, Bo Lu
Journal: Journal of Hematology & Oncology (2016)

Pembrolizumab is a monoclonal antibody that is designed against programmed cell death protein 1 (PD-1). Pembrolizumab and other immunocheckpoint-blocking monoclonal antibodies work by modulating a patient's own immune system to increase anti-tumor activity. While immunocheckpoint blockade has shown promising results, only 20–40 % of patients experience objective clinical benefit. Differences in individual tumor biology and the presence multiple immune checkpoints present a challenge for treatment. Because radiotherapy has immunomodulatory effects on the tumor microenvironment, it has the potential to synergize with immunotherapy and augment tumor response. NCT02318771 is a phase 1 clinical trial designed to investigate the immunomodulatory effects of radiation therapy in combination with pembrolizumab. The patient is a 64-year-old male with metastatic clear cell renal cell carcinoma, Fuhrman grade 4, pathologically staged as T3 N0. Metastatic disease was well controlled for several years with sunitinib. Following disease progression, he was switched to axitinib. When disease progression continued, the patient was enrolled in NCT02318771, a phase 1 clinical trial combining radiotherapy and pembrolizumab. The patient experienced unusually rapid disease progression during treatment, which was confirmed by repeated CT scans to rule out pseudoprogression. Tissue biopsies and peripheral blood draws were obtained before, during, and after treatment. Samples were analyzed to provide plausible rationale for rapid treatment failure. Biomarker analysis demonstrated an absence of TILs, which may be a cause of treatment failure as pembrolizumab works through T cell-dependent mechanisms. Furthermore, the presence of other non-redundant immune checkpoints in the periphery and tumor microenvironment presents a treatment challenge. Additionally, the radiation dose and fractionation schedule may have played a role in treatment failure as these factors play a role in the effect radiotherapy on the tumor microenvironment as well as the potential for synergy with immunotherapy. An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer, NCT02318771 .
Of HIV, Kings, and Cures: Troubling the Apocryphal Apothecary
Authors: Adrian Guta, Peter A. Newman
Journal: The American Journal of Bioethics (2016)

This is an Accepted Manuscript of an article published by Taylor & Francis in the American Journal of Bioethics in 2016, available at http://www.tandfonline.com/doi/full/10.1080/15265161.2016.1214313
Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma
Authors: G. Roth, Z. Macek-Jilkova, A. Zeybek, G. Abbadessa, Y. Yu, P. Marche, V. Leroy, T. Decaens
Journal: Journal of Hepatology (2016)
P0269 : The insuline-like growth factor 2 (IGF2) MRNA binding protein (IMP) p62 promotes cirrhosis-linked hepatocarcinogenesis
Authors: S.M. Kessler, B. Czepukojc, K. Engel, N. Van Hul, J. Haybaeck, I. Leclercq, A.K. Kiemer
Journal: Journal of Hepatology (2015)
Lkb1 Activates Ras Pathway in Hepatocellular Carcinoma by Transcriptional and Post-Translational Regulation of Rasgrp3
Authors: J. García-Rodríguez, I. Zubiete-Franco, D. Fernández-Ramos, P. Fernández-Tussy, L. Barbier-Torres, F. Lopitz-Otsoa, V. Gutiérrez-de Juan, C. Martín, P. Aspichueta, E. Villa, A. Fernández, M. Fraga, P. Iruzubieta, J. Crespo, J. Lozano, L. Boix, J. Bruix, D. Calvisi, M. Varela-Rey, N. Beraza, S. Lu, J. Mato, T.C. Delgado, M.L. Martínez-Chantar
Journal: Journal of Hepatology (2016)
Resistance Analysis of Genotype 1 or 3 HCV-Infected Patients Treated with Sofosbuvir/Velpatasvir+GS-9857 for 6 or 8 Weeks
Authors: E. Gane, E.S. Svarovskaia, H. Dvory-Sobol, R.H. Hyland, L.M. Stamm, D.M. Brainard, M.D. Miller, H. Mo, C. Schwabe, C.A. Stedman
Journal: Journal of Hepatology (2016)
Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL
Authors: L. Fransecky, M. Neumann, S. Heesch, C. Schlee, J. Ortiz-Tanchez, S. Heller, M. Mossner, S. Schwartz, L. H. Mochmann, K. Isaakidis, L. Bastian, U. R. Kees, T. Herold, K. Spiekermann, N. Gökbuget, C. D. Baldus
Journal: Journal of Hematology & Oncology (2016)

GATA3 is pivotal for the development of T lymphocytes. While its effects in later stages of T cell differentiation are well recognized, the role of GATA3 in the generation of early T cell precursors (ETP) has only recently been explored. As aberrant GATA3 mRNA expression has been linked to cancerogenesis, we investigated the role of GATA3 in early T cell precursor acute lymphoblastic leukemia (ETP-ALL).We analyzed GATA3 mRNA expression by RT-PCR (n = 182) in adult patients with T-ALL. Of these, we identified 70 of 182 patients with ETP-ALL by immunophenotyping. DNA methylation was assessed genome wide (Illumina Infinium® HumanMethylation450 BeadChip platform) in 12 patients and GATA3-specifically by pyrosequencing in 70 patients with ETP-ALL. The mutational landscape of ETP-ALL with respect to GATA3 expression was investigated in 18 patients and validated by Sanger sequencing in 65 patients with ETP-ALL. Gene expression profiles (Affymetrix Human genome U133 Plus 2.0) of an independent cohort of adult T-ALL (n = 83) were used to identify ETP-ALL and investigate GATA3low and GATA3high expressing T-ALL patients. In addition, the ETP-ALL cell line PER-117 was investigated for cytotoxicity, apoptosis, GATA3 mRNA expression, DNA methylation, and global gene expression before and after treatment with decitabine.In our cohort of 70 ETP-ALL patients, 33 % (23/70) lacked GATA3 expression and were thus defined as GATA3low. DNA methylation analysis revealed a high degree of GATA3 CpG island methylation in GATA3low compared with GATA3high ETP-ALL patients (mean 46 vs. 21 %, p < 0.0001). Genome-wide expression profiling of GATA3low ETP-ALL exhibited enrichment of myeloid/lymphoid progenitor (MLP) and granulocyte/monocyte progenitor (GMP) genes, while T cell-specific signatures were downregulated compared to GATA3high ETP-ALL. Among others, FLT3 expression was upregulated and mutational analyses demonstrated a high rate (79 %) of FLT3 mutations. Hypomethylating agents induced reversal of GATA3 silencing, and gene expression profiling revealed downregulation of hematopoietic stem cell genes and upregulation of T cell differentiation.We propose GATA3low ETP-ALL as a novel stem cell-like leukemia with implications for the use of myeloid-derived therapies.
The influence of medical comorbidities on the presentation and outcome of stage I-III non-small cell lung cancer.
Authors: N. Mehta, J. Yorio, A. Avila, J. Yan, Y. Xie, D. E. Gerber
Journal: Journal of Clinical Oncology (2010)

e17508 Background: Non-small cell lung cancer (NSCLC) outcomes vary widely among patients. We previously reported the associations between several clinical characteristics and outcomes among patients with stage I-III NSCLC at a medical center providing care to a diverse patient population [Yorio et al. J Clin Oncol 27:15s, 2009 (suppl; abstr 7534)]. To determine potential reasons for these associations, we incorporated a validated medical comorbidity index into the analysis. Methods: We performed a retrospective analysis of consecutive patients diagnosed with NSCLC stages I-III from 2000 to 2005 at the University of Texas Southwestern Medical Center. Demographic, tumor, and comorbidity data were obtained from hospital tumor registries, administrative databases, and individual patient records. The association between these variables was assessed using univariate analysis, multivariate logistic regression, and survival analysis. Results: A total of 478 patients met criteria for analysis. Median age was 64 years, and 52% were men. A higher Charlson Comorbidity Index (CCI) was associated with a lower likelihood of presentation with locally advanced (stage III) disease (OR 0.58; 95% CI, 0.38 to 0.88; p=0.01). In univariate analysis, overall survival was associated with age, gender, race, insurance type, stage, histology, and CCI. In multivariate logistic regression, overall survival remained associated with all variables: age (p=0.0001), gender (p=0.001), race (p=0.01), insurance type (p=0.01), stage (p<0.0001), histology (p=0.003), and CCI (p=0.0007). The CCI was associated with survival for patients with both early stage (I-II) and locally advanced (stage III) disease (p=0.02 and p=0.01, respectively). Conclusions: In this cohort of patients with stage I-III NSCLC, the presence of comorbidities was associated with diagnosis at an earlier disease stage. Although comorbidities were significantly associated with outcome in both early stage and locally advanced disease, they did not fully account for survival differences based on age, gender, race, insurance type, stage, and histology. These findings warrant further study. No significant financial relationships to disclose.
Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Children’s Oncology Group (COG).
Authors: Steven G. DuBois, Rajen Mody, Collin Van Ryn, Arlene Naranjo, Susan G. Kreissman, David Baker, Marguerite T Parisi, Barry L. Shulkin, John M. Maris, Vandana Batra, Julie R. Park, Katherine K. Matthay, Gregory A Yanik
Journal: Journal of Clinical Oncology (2016)

10526 Background: Prior investigations suggest that neuroblastomas (NBL) that do not accumulate MIBG (MIBG non-avid) may have more favorable features compared to MIBG avid tumors. We compared clinical/biologic features and clinical outcomes between patients with MIBG non-avid vs. avid NBL. Methods: A retrospective analysis was performed of patients with metastatic high- or intermediate-risk NBL treated on COG protocols A3973 or A3961, respectively. A3973 patients had baseline MIBG scans centrally reviewed (n = 306). A3961 patients with bone metastasis at baseline were included (n = 37). Comparisons of clinical/biological features according to MIBG avidity were made with chi-squared or Fisher exact tests. Event-free survival (EFS) was compared using log-rank tests and modeled using Cox models. Results: Thirty of 343 patients (8.7%) in the analytic cohort had MIBG non-avid NBL (n = 1 from A3961 and n = 29 from A3973). Non-avid tumors were less likely to be adrenal primary tumors (34.5% vs. 57.2%; p = 0.02) or have bone metastases (36.7% vs. 61.7%; p = 0.008) and were more likely MYCN amplified (53.8% vs. 32.6%; p = 0.03). The rate of positivity for urine catecholamine levels (available from A3973 only) was lower in patients with non-avid NBL (66.7% vs. 91%; p < 0.001). Patients with MIBG non-avid NBL had a 5-year EFS of 50.0% compared to 38.7% for patients with MIBG avid NBL (p = 0.03). On backward-selected multivariate testing in high-risk patients, MIBG avidity was the sole adverse prognostic factor for EFS identified (hazard ratio 1.77; 95% confidence interval 1.04 – 2.99; p = 0.03); MYCN status, age, grade, MKI, and ploidy were not prognostic. Conclusions: MIBG non-avid NBL represents a distinct clinical subgroup with lower rates of adrenal primary tumors, bone metastasis, and catecholamine secretion. Despite being more likely to have MYCN amplified tumors, patients with MIBG non-avid NBL have superior outcomes compared to patients with MIBG avid NBL.
Clif-C ALF Score is a New Prognostic Tool to Identify Liver Transplant Candidates in Patients with Paracetamol Related Acute Liver Failure and it can Predict the Futility of Liver Transplantation
Authors: F. Figorilli, O. Roux, A. Putignano, P. Houssel, C. Francoz, C. Paugam, B. Agarwal, F. Durand, R. Jalan
Journal: Journal of Hepatology (2016)
Very Early Death (&lt;2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk Features Of Both The Disease and The Patient
Authors: Efstathios Kastritis, Evangelos Terpos, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Despoina Kalapanida, Magdalini Migkou, Nikolaos Kanellias, Dimitrios Christoulas, Dimitra Gika, Despoina Mparmparoussi, Charis Matsouka, Meletios A. Dimopoulos
Journal: Blood (2013)
Unphosphorylated ISGF3 Drives the Basal Transcription of Interferon-Stimulated Genes to Defend HCV and HEV Infections
Authors: W. Wang, Y. Yin, L. Xu, Y. Wang, X. Zhou, L.J.W. Van Der Laan, D. Sprengers, H. Metselaar, M. Peppelenbosch, Q. Pan
Journal: Journal of Hepatology (2016)
Intensive glucose-lowering in type 2 diabetes was linked to hypoglycemia in high-complexity patients
Authors: Daniel I. Steinberg
Journal: Annals of Internal Medicine (2016)

ACP Journal Club20 September 2016Intensive glucose-lowering in type 2 diabetes was linked to hypoglycemia in high-complexity patientsDaniel I. Steinberg, MDDaniel I. Steinberg, MDIcahn School of Medicine at Mount Sinai, New York City, New York, USA (D.I.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2016-165-6-033 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationMcCoy RG, Lipska KJ, Yao X, et al. Intensive treatment and severe hypoglycemia among adults with type 2 diabetes. JAMA Intern Med. 2016; 176:969-78. https://pubmed.ncbi.nlm.nih.gov/27273792Clinical Impact RatingsGIM/FP/GP: Hospitalists: Endocrinology: References1 AGS Choosing Wisely Workgroup. American Geriatrics Society identifies five things that healthcare providers and patients should question. J Am Geriatr Soc. 2013;61:622-31. [PMID: 23469880] Google Scholar2 Sussman JB, Kerr EA, Saini SD, et al. Rates of deintensification of blood pressure and glycemic medication treatment based on levels of control and life expectancy in older patients with diabetes mellitus. JAMA Intern Med. 2015;175:1942-9. [PMID: 26502220] Google Scholar3 American Diabetes Association. 10. Older adults. Diabetes Care. 2016;39 Suppl 1:S81-5. [PMID: 26696686] Google Scholar Author, Article, and Disclosure InformationAffiliations: Icahn School of Medicine at Mount Sinai, New York City, New York, USA (D.I.S.)This article was published at Annals.org on 6 September 2016. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 20 September 2016Volume 165, Issue 6Page: JC33KeywordsDementiaGeriatricsHbA1cHealth careHemoglobinHypoglycemiaInsulinRenal failureSystematic reviewsType 2 diabetes ePublished: 20 September 2016 Issue Published: 20 September 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Treatment of Hepatitis C Virus in Patients with Advanced Cirrhosis: Always Justified? Analysis of the Hepa-C Registry
Authors: C. Fernández-Carrillo, S. Lens, E. Llop, J.M. Pascasio, I. Fernández, C. Baliellas, J. Crespo, M. Buti, L. Castells, M. Romero-Gómez, C. Pons, J.M. Moreno, A. Albillos, C. Fernández-Rodríguez, M. Prieto, M. Fernández-Bermejo, J. García-Samaniego, J.A. Carrión, M. de la Mata, E. Badia, J. Salmerón, J.I. Herreros, M. Salcedo, J.J. Moreno, J. Turnes, R. Granados, M. Blé, J.L. Calleja
Journal: Journal of Hepatology (2016)
Granulocyte Colony-Stimulating Factor (G-CSF) Levels in a Randomized, Controlled Acupuncture Trial for Chemotherapy-Induced Neutropenia.
Authors: Weidong Lu, Ursula A. Metulonis, Anne Doherty-Gilman, Hang Lee, Elizabeth Dean-Clower, Andrew Rosulek, Carolyn Gibson, Annekathryn Goodman, Roger B. Davis, Julie E. Buring, Peter M. Wayne, Richard T. Penson, David S. Rosenthal
Journal: Blood (2007)
Neurofunctional Characterization of Patients with Primary Biliary Cholangitis and Fatigue
Authors: R. Zenouzi, J. von der Gablentz, M. Heldmann, M. Göttlich, A. Fellbrich, C. Weiler-Normann, M. Sebode, C. Schramm, T.F. Münte, A.W. Lohse
Journal: Journal of Hepatology (2016)
The New Generation Pan-Ppar Agonist Iva337 Protects the Liver from Metabolic Disorders and Fibrosis
Authors: G. Wettstein, C. Estivalet, J. Tessier, P.T. Boustugue, I. Jantzen, E. Defrene, F. Kupkowski, P. Faye, V. Adarbes, J.-M. Germain, E. Vasseur, C. Robert, C. Fromond, P. Broqua, J.-L. Junien, J.-M. Luccarini, I. Konstantinova
Journal: Journal of Hepatology (2016)
Effect of Amiodarone and HCV Direct-Acting Antiviral Agents on Cardiac Conduction in Nonclinical Studies
Authors: G. Liu, C.H. Tay, S. Rajamani, A. Ray, L. Stamm, J. Vick, M. Wilichinsky, J. McHutchison, D. Brainard
Journal: Journal of Hepatology (2016)
Impact on Renal Function of Stepwise Withdrawal of Tacrolimus Combined with Everolimus and EC-MPS vs Standard Treatment Combining Tacrolimus and EC-MPS in De Novo Liver Transplant Recipients: Results of the Simcer Study
Authors: F. Conti, F. Saliba, C. Duvoux, S. Dharancy, J. Dumortier, F. Di Giambattista, Y. Calmus
Journal: Journal of Hepatology (2016)
Incarceration of People who inject Drugs – Modelling its Role in HCV Transmission and the Impact of Scaled-Up HCV Treatment in Prisons
Authors: J. Stone, N.K. Martin, M. Hickman, S. Hutchinson, E. Aspinall, A. Taylor, A. Munro, K. Dunleavy, E. Peters, P. Bramley, P. Hayes, D. Goldberg, P. Vickerman
Journal: Journal of Hepatology (2016)